Choose Your Language Close

Engineering the medical revolution

A decade ago, we founded Molecular Health with a vision to change healthcare. Today we are leaders in the development and application of information technology to prevent and treat disease.

Precision medicine through technology

Decoding of the first human genome in 2000 ushered in a new vision of medicine. Known as precision medicine, it aims to find the best possible treatment for each patient based on his or her individual genetic uniqueness. Today every patient can benefit from the scientific and technological innovations in the field of human genome analysis.

The challenge of precision medicine is to combine the molecular and clinical information of a single patient with the relevant biomedical knowledge in a way that yields practical application. A completely new type of information technology is needed to meet this challenge. 

Molecular Health is at the forefront of this paradigm shift. Using technology and science together, we create groundbreaking products that help to radically improve the prevention and treatment of diseases like cancer.

How it works

Molecular Health offers a unique biomedical technology platform. Our core technology is Nucleus—the biggest and most comprehensive biomedical data warehouse in the world.

The Nucleus technology paves the way for our products, which are designed to analyze and interpret complex molecular and clinical patient information on the basis of the knowledge in Nucleus to enable precision medicine.

Press Releases

Molecular Health Raises €25 Million in Private Financing

Proceeds to further build commercial infrastructure and drive product adoption

Heidelberg, Germany, Boston, MA – November 16, 2015 – Molecular Health, a leader in cloud-based healthcare decision support technology to enable evidence-based treatment decisions and improved outcomes, today announced that it has raised €25 million in private financing to expand commercial adoption of its healthcare decision engine. The round was led by current investor dievini, an investor in global life and health sciences companies. With the completion of this round of financing, Molecular Health has raised a total of approximately €100 million.

Read more

Molecular Health Opens Berlin Office to Support Growing Demand for Digital Health Solutions

Company strengthens relationships with policy makers and patient advocacy groups

Heidelberg, Germany, Boston, MA – November 13, 2015— Molecular Health, a leader in cloud-based healthcare decision support technology to enable evidence-based treatment decisions and improved outcomes, today announced that the company has opened an office in Berlin, Germany to accelerate the growing European demand for its suite of digital health solutions.

Read more

Molecular Health Identifies Biomarker for Tumor Growth Related to Cancer Anemia Treatment

Results published today in Cancer Cell validate new diagnostic biomarker for reducing adverse events and improving outcomes of cancer patients with anemia

Findings enable potential patient stratification for tailored treatment

Cambridge, MA – October 15, 2015— Molecular Health, a leader in cloud-based healthcare decision support technology to enable evidence-based treatment decisions and improved outcomes, today announced data that identify and confirm the discovery that ephrin-type B receptor 4 (EPHB4) is an alternative erythropoietin (EPO) receptor. Moreover, it was found that EPHB4 has significant predictive value for guiding EPO use in anemic cancer patients, as patients with tumors expressing EPHB4 are likely to experience poorer outcomes in response to EPO, due to the “triggering” of tumor growth and progression.

Read more

Molecular Health to Offer Early Access Program for SafetyMAP

Enrollment Now Open for Early Access Program (EAP) Set to launch in November 2015

Cambridge, MA – October 5, 2015 – Molecular Health, a leader in cloud-based healthcare decision support technology to optimize the selection of therapies for improved patient outcomes, today announced that it will initiate an early access program (EAP) offering its SafetyMAPTM software to pharmaceutical companies and clinical professionals involved in drug safety starting in November 2015.

Read more

EMC to assume costs of tumor analysis for employees and relatives with cancer

The "Corporate Oncology Program for Employees" with Molecular Health

Schwalbach/Heidelberg - September 23, 2015 - As of September 1, 2015, EMC in Germany will be joining forces with Molecular Health to launch a Corporate Oncology Program for Employees (COPE). If an EMC employee or the spouse, partner, or child of an EMC employee are diagnosed with cancer, the program will fund an analysis of the patient's tumor genome so that the most promising treatment options can be identified.

Read more

Molecular Health Licenses SafetyMAP™ to the U.S. Food and Drug Administration (FDA)

Cambridge, MA – September 9, 2015 – Molecular Health has entered into a commercial license to provide the FDA with use of its SafetyMAP™ software - formerly known as Molecular Analysis of Side Effect information (MASE™), to provide a comprehensive and dynamic analytical solution for the detection and molecular analysis of drug-induced adverse events for all marketed drugs and for predicting safety issues of new drug candidates.  The license supplies the FDA with access to SafetyMAP for 10 concurrent users for a period of one year and can be extended for two additional years at the discretion of the FDA.

Read more

Tumor biomarkers are essential but not sufficient for predicting cancer drug response

Germline biomarkers predicted drug toxicity: impact on clinical routine

June 30, 2015, Heidelberg/Cambridge, MA. A core tenet of precision medicine is that predictive biomarkers can enhance therapeutic decision-making. In a new pilot study, scientists at Molecular Health analyzed a randomly selected set of 250 patients with solid tumors and detected predictive biomarkers in more than 85% of tumors.

Read more

Beyond Hotspots

Many tests for predictive biomarkers in tumors focus on selected known mutations

June 29, 2015. Heidelberg / Cambridge, MA. Many tests for predictive biomarkers in tumors focus on selected known mutations or regions (e.g., hotspot panels). In a new study, scientists at Molecular Health examined the rates of secondary mutations in known biomarker genes and their potential impact on the diagnostic reliability of specific single-nucleotide variant (SNV) biomarker testing.

Read more

Molecular Health Signs Distribution Agreement with TestAnalytika for Latin American Region

June 4, 2015
Cambridge, MA, Houston, TX – Molecular Health signed an agreement with TestAnalytika to be its preferred distributor in the Latin American region at the 2015 ASCO Annual Meeting.  TestAnalytika will begin to market and distribute Molecular Health’s cancer treatment decision support product, TreatmentMAP™, to patients, physicians, hospitals, laboratories, cancer centers and insurers in Latin America later this year.

Read more

New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States

The Guardian Research Network and Molecular Health will Provide Cancer Patients with Personalized Clinical Decision Support

CAMBRIDGE, Massachusetts and SPARTANBURG, South Carolina, May 29, 2015

The Guardian Research Network and Molecular Health have announced a collaboration designed to provide therapeutic clinical trial access and molecular diagnostic decision support to the majority of cancer patients living in U.S. communities.

Read more

Molecular Health Wins SAP HANA® Innovation Award in "Technology Trailblazer - Business Application" Category at SAPPHIRE® NOW Conference

May 8, 2015 Cambridge, MA / Heidelberg, Germany - Molecular Health today announced it has won an SAP HANA® Innovation Award in the category Technology Trailblazer - Business Application. The awards presented by SAP SE (NYSE: SAP) recognize the extraordinary ways that customers are using the SAP HANA platform to transform their business and society. 

Read more

Molecular Health gains patent for novel receptor utilizing computational biomarker discovery technology

Addresses unmet need in treatment of millions of cancer patients

April 27, 2015 Cambridge, MA / Heidelberg, Germany -- Molecular Health announced today it has been granted a patent in Europe entitled “Tissue Protective Erythropoietin Receptor”. This latest patent supports Molecular Health’s discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth. 

Read more

GATC Biotech signs a sales and marketing agreement for products and services with Molecular Health

  • GATC Biotech to play an essential role in the commercialisation of TreatmentMAP™
  • Significantly increased access to the first registered medical device for personalised cancer medicine in Europe
  • GATC Biotech expands the market reach and opportunities of its Diagnostic Solutions division
Constance, Germany, 21 April 2015: GATC Biotech, provider of innovative, high quality DNA and RNA sequencing solutions to the pharmaceutical and diagnostics markets, announced today that it has signed a commercial agreement with Molecular Health.

Read more

Molecular Health to Present at Personalized Medicine World Conference

HEIDELBERG, Germany & THE WOODLANDS, Texas--(BUSINESS WIRE)--Molecular Health announced today that its chief innovation officer, David Jackson, Ph.D., will speak at this year’s Personalized Medicine World Conference, Silicon Valley. Dr. Jackson’s presentation, titled, “From Knowledge Innovation to Personalized Pharmacovigilance,” will highlight how the integrated computational analysis of genetic, pharmacological and clinical parameters can be used to identify safer effective treatment options for cancer patients. 

Read more